中国肿瘤临床
中國腫瘤臨床
중국종류림상
Chinese Journal of Clinical Oncology
2015年
19期
942-946
,共5页
非小细胞肺癌%EGFR突变%EGFR-TKI%耐药
非小細胞肺癌%EGFR突變%EGFR-TKI%耐藥
비소세포폐암%EGFR돌변%EGFR-TKI%내약
non-small cell lung cancer%epidermal growth factor receptor mutation%epidermal growth factor receptor tyrosine-ki-nase inhibitor%resistance
表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinease inhibitors,EGFR-TKIs)对EGFR敏感突变非小细胞肺癌(nonsmall cell lung cancer,NSCLC)除了其卓越的疗效,也如其他药物一样最终不可避免地发生耐药.EGFR基因突变是最常见的肺癌驱动基因之一,针对EGFR-TKI耐药后的处理,目前虽无固定治疗模式,但临床进行了大量的探索性研究及治疗对策的探讨,部分结果对临床治疗这类患者有一定启示.本文将就近年具有代表性的研究及进展做一论述.
錶皮生長因子受體酪氨痠激酶抑製劑(epidermal growth factor receptor-tyrosine kinease inhibitors,EGFR-TKIs)對EGFR敏感突變非小細胞肺癌(nonsmall cell lung cancer,NSCLC)除瞭其卓越的療效,也如其他藥物一樣最終不可避免地髮生耐藥.EGFR基因突變是最常見的肺癌驅動基因之一,針對EGFR-TKI耐藥後的處理,目前雖無固定治療模式,但臨床進行瞭大量的探索性研究及治療對策的探討,部分結果對臨床治療這類患者有一定啟示.本文將就近年具有代錶性的研究及進展做一論述.
표피생장인자수체락안산격매억제제(epidermal growth factor receptor-tyrosine kinease inhibitors,EGFR-TKIs)대EGFR민감돌변비소세포폐암(nonsmall cell lung cancer,NSCLC)제료기탁월적료효,야여기타약물일양최종불가피면지발생내약.EGFR기인돌변시최상견적폐암구동기인지일,침대EGFR-TKI내약후적처리,목전수무고정치료모식,단림상진행료대량적탐색성연구급치료대책적탐토,부분결과대림상치료저류환자유일정계시.본문장취근년구유대표성적연구급진전주일논술.
Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) have elicited curative effects on patients with advanced non-small cell lung cancer and with activating mutations in the EGFR gene. However, acquired resistance to EGFR-TKIs is eventually developed after an initial response is induced;as such, patients with acquired resistance must be treated with more ef-fective strategies to delay or possibly overcome the resistance. This article reviews available data on the treatment of patients who have failed to respond to EGFR-TKI.
